Improving Post-COVID (Long COVID) Syndrome with Hyperbaric Oxygen (PCS-HBOT)

​

Status: Active - Recruitment Completed

​

The Post COVID-19 condition (Long COVID) is creating a growing strain on healthcare, and current treatments mostly focus on managing symptoms. This pilot study will evaluate if hyperbaric oxygen therapy (HBOT) is feasible and acceptable for patients, while also exploring whether HBOT can improve many of the symptoms associated with the condition like fatigue, brain fog, and difficulty with exertion. Patients will be randomly assigned to start treatment immediately or after 60 days of observation. Results will help plan future trials and guide care for post COVID-19 patients.

​

​

Hyperbaric Oxygen Therapy for Endometriosis Pain (HEROES)

​

Status: Active - Recruiting Open

​

Endometriosis causes chronic pelvic pain and significantly impacts quality of life, with current treatments often providing limited relief. This randomized trial will investigate whether adding hyperbaric oxygen therapy (HBOT) to standard multi-modal care can reduce pain, decrease opioid use, and improve quality of life for women with severe, treatment-resistant endometriosis. Participants will be randomized to receive standard care alone or with 40 HBOT sessions. Pain, opioid consumption, and quality of life will be assessed over six months, alongside safety, adherence, and cost measures. Results aim to evaluate HBOT as a potential new therapy and improve care for endometriosis patients.

​​

​

Implementation of a Care Pathway including HBOT for Sudden Hearing Loss

​

Status: Active 

​

This quality improvement study aims to address timely management of idiopathic sudden sensorineural hearing loss (ISSNHL) through a standardized care pathway involving prompt otology referral, oral and intratympanic steroids, and adjunctive hyperbaric oxygen therapy (HBOT). Patients will be assessed for hearing improvement, tinnitus, and treatment side effects, with data collected from electronic medical records and follow-ups over 4–6 months. The study evaluates whether this pathway reduces time to treatment and improves auditory outcomes compared to historical controls. Results will inform best practices, optimize care access, and be disseminated widely to the ENT and hyperbaric communities.

​​

​

Using Multispectral Near Infrared Imaging to Assess Wounds Treated with HBOT

​

Status: Active 

​

This observational study evaluates the use of hyperbaric oxygen therapy (HBOT) for chronic lower extremity wounds and investigates whether multispectral near-infrared spectroscopy (MS-NIRS) imaging can predict or monitor treatment response. Using a specialized FDA approved device, tissue oxygenation and temperature will be measured at baseline, during, and after HBOT sessions in 60 participants. Wounds will be assessed using standardized grading systems, thermography, and wound measurements. The study aims to improve understanding of HBOT mechanisms, optimize treatment protocols, and enhance clinical outcomes for chronic wound patients.

​​​

​

PENATACLO with Hyperbaric Oxygen Therapy for ORN

​

Status: Active ​

​

This study addresses osteoradionecrosis, a severe complication of head and neck cancer radiation that causes non-healing bone and significantly impacts quality of life. Standard treatments are often ineffective, and supplemental options include hyperbaric oxygen therapy (HBOT) or the oral drug combination PENTOCLO. The study will randomly assign patients to receive either HBOT alone or HBOT plus PENTOCLO, tracking pain, side effects, and the need for surgery. Findings will inform a future larger trial to determine the most effective treatment approach.

​​​

​

Hyperbaric Oxygen Therapy in Treatment of Brain Radiation Necrosis (HOT-BRAIN)

​

Status: Pending Start

​

This study investigates the use of hyperbaric oxygen therapy (HBOT) for managing early-stage brain radiation-induced necrosis, a complication of brain cancer radiation that damages healthy tissue. Current treatments like steroids and Bevacizumab have limitations due to ineffectiveness, toxicity, or high cost. This study aims to evaluate whether HBOT can improve quality of life, reduce steroid use, and limit reliance on Bevacizumab, potentially offering a safer and more cost-effective treatment option.

​​

​

Intravenous Ketamine and Immersive Virtual Reality to Treat Depression (TREASURE)

​

Status: Pending Start - Run by Ontario Ketamine and Infusion Centre

​

This pilot trial investigates the feasibility and preliminary efficacy of combining virtual reality (VR) with ketamine therapy (VR-K) for adults with treatment-resistant depression (TRD). Phase I will refine custom VR environments based on patient feedback, while Phase II will randomize 26 participants to receive either standard ketamine treatment or VR-K to assess protocol feasibility and potential synergistic antidepressant effects. Outcomes include mood, anxiety, cognitive function, neural activity, side effects, and patient satisfaction. The study aims to inform a larger trial and evaluate whether VR-K can enhance ketamine’s antidepressant effects and reduce relapse.

​

​